The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

OBJECTIVE: A 12-week study assessed the efficacy and safety of a new oral antidiabetic agent, imeglimin, as add-on therapy in type 2 diabetes patients inadequately controlled with metformin alone. RESEARCH DESIGN AND METHODS: A total of 156 patients were randomized 1:1 to receive imeglimin (1,500 mg...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Fouqueray, Pascale, Pirags, Valdis, Inzucchi, Silvio E., Bailey, Clifford J., Schernthaner, Guntram, Diamant, Michaela, Lebovitz, Harold E.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Diabetes Association 2013
Θέματα:
Original Research
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3579350/
https://ncbi.nlm.nih.gov/pubmed/23160726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc12-0453
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια